LEAMINGTON,
Ontario, June 29, 2022 (GLOBE NEWSWIRE) --PRESS RELEASE-- Tilray Brands, Inc.(Nasdaq: TLRY; TSX: TLRY), a global cannabis-lifestyle and consumer packaged goods company today
announced that its medical cannabis division, Tilray Medical, has expanded its
medical cannabis offerings in the United Kingdom. Tilray Medical now offers the
broadest portfolio of cannabis flower in the UK market today, including a
differentiated range of high THC products, cultivated at its EU-GMP-certified
facility in Portugal.
Denise
Faltischek, Tilray’s Chief Strategy Officer, and Head of International
Business, said, “The demand for medical cannabis in the UK is growing rapidly.
We are incredibly proud to provide patients in the UK with high-quality,
consistent medical cannabis products they can rely on and are accessible to
them.”
Tilray Medical
now offers an extensive selection of medical cannabis products including a
market leading portfolio of cannabis flowers with THC potencies that span from
10% to 25% and offer a range of different ratios. Tilray Medical’s
portfolio in the UK is underpinned by a breadth of cultivars, each with a
unique profile of cannabinoids and terpenes, that have been selected to ensure
patients can receive both the highest product quality as well as consistency
when it comes to supply of their medicinal cannabis products. By offering such
a broad range of cannabis flower products in the UK, Tilray Medical hopes to
expand the range of treatment options available to patients and ensure
prescribers and patients are provided with a safe and reliable choice as they
embark on their medical cannabis journey.
In the UK,
patients may obtain prescriptions for medical cannabis through their specialist
doctor. Tilray Medical supplies the UK and the rest of our international
business with EU-GMP certified medical cannabis from our state-of-the-art
facilities in Portugal, providing patients with safe and reliable access to
high-quality medical cannabis.
